<?xml version="1.0" encoding="UTF-8"?>
<p id="p0045">The present control strategies of the disease include the reduction of secondary infections by early diagnosis and isolation of cases, providing optimal care to infected patients, and the development of effective diagnostic, preventive and therapeutic strategies, including vaccines (
 <xref rid="bb0435" ref-type="bibr">WHO, 2020</xref>). In the absence of any proven treatment option, many drugs are under investigation to control this disease with a potentially fatal outcome. Chloroquine is one of the widely used drugs, with in vitro evidence that it reduces viral replication (
 <xref rid="bb0110" ref-type="bibr">Deponti et al., 2017</xref>). A combination of hydroxychloroquine and azithromycin has also been found to have a significant synergistic effect in reducing viral load and early recovery (
 <xref rid="bb0135" ref-type="bibr">Gautret et al., 2020</xref>). For severe disease, the use of steroids, passive antibodies, and selective cytokine blockade is suggested (
 <xref rid="bb0250" ref-type="bibr">Mehta et al., 2020</xref>). The role of NSAIDs and corticosteroids, however, is still controversial and not advisable at present (
 <xref rid="bb0350" ref-type="bibr">Russell et al., 2020</xref>). Antivirals such as interferon-Î±, lopinavir/ritonavir, ribavirin, etc. are also being used as a tentative treatment for Covid-19 (
 <xref rid="bb0115" ref-type="bibr">Dong et al., 2020</xref>). Yet, as of now, there are no specific antiviral drugs or vaccines verified to be effective against SARS-CoV-2, hence the emphasis is being laid on preventive measures and symptomatic treatment (
 <xref rid="bb0190" ref-type="bibr">Jean et al., 2020</xref>).
</p>
